Evidence map›Paper›PMID 40038760›Full record

ArticleJournal of neuroinflammation2025

The protective PLCγ2-P522R variant mitigates Alzheimer's disease-associated pathologies by enhancing beneficial microglial functions.

Mari Takalo, Heli Jeskanen, Taisia Rolova, Inka Kervinen, Marianna Hellén, Sami Heikkinen, Hennariikka Koivisto, Kimmo Jokivarsi, Stephan A Müller, Esa-Mikko Koivumäki and 23 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Aberrant phase separation from a rare ABI3 mutation drives microglial dysfunction and Alzheimer's risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Mari Takalo *Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. mari.takalo@uef.fi.
Heli Jeskanen *Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Taisia RolovaNeuroscience Center, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Inka KervinenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Marianna HellénNeuroscience Center, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Sami HeikkinenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Hennariikka KoivistoA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Kimmo JokivarsiA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Stephan A MüllerGerman Center for Neurodegenerative Diseases (DZNE Munich), Munich, Germany.
Esa-Mikko KoivumäkiTurku PET Centre, University of Turku, Turku, Finland.
Petra MäkinenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Sini-Pauliina JuopperiInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Roosa-Maria WillmanInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Rosa SinisaloInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Dorit HoffmannA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Henna JänttiA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Michael PeitzInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn, Bonn, Germany.
Klaus FließbachDepartment of Old Age Psychiatry and Cognitive Disorders, University of Bonn Medical Center, Bonn, Germany.
Teemu KuulasmaaInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Teemu NatunenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Susanna KemppainenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Pekka PoutiainenDiagnostic Imaging Center, Kuopio University Hospital, Kuopio, Finland.
Ville LeinonenDepartment of Neurosurgery, Kuopio University Hospital, Kuopio, Finland.
Tarja MalmA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Henna MartiskainenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Alfredo RamirezGerman Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.
Annakaisa HaapasaloA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Stefan F LichtenthalerGerman Center for Neurodegenerative Diseases (DZNE Munich), Munich, Germany.
Heikki TanilaA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Christian HaassGerman Center for Neurodegenerative Diseases (DZNE Munich), Munich, Germany.
Juha RinneTurku PET Centre, University of Turku, Turku, Finland.
Jari KoistinahoNeuroscience Center, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Mikko HiltunenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland. mikko.hiltunen@uef.fi.

Funding

Alzheimer's Association ADSF-24-1284326-CBundesministerium für Bildung und Forschung grant 01ED2007ABundesministerium für Bildung und Forschung grant, ClinspectM FKZ161L0214CInnovative Medicines Initiative 2 Joint Undertaking which receives support from the European Union's Horizon 2020 research and innovation programme 115975JPco-fuND-2 'Multinational research projects on Personalized Medicine for Neurodegenerative Diseases' (PMG-AD) 334802Research Council of Finland 330178Research Council of Finland 337530Research Council of Finland 338182Research Council of Finland 355604the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy) 390857198
6 · The paper itself

Abstract

backgroundPhospholipase C gamma 2, proline 522 to arginine (PLCγ2-P522R) is a protective variant that reduces the risk of Alzheimer's disease (AD). Recently, it was shown to mitigate β-amyloid pathology in a 5XFAD mouse model of AD. Here, we investigated the protective functions of the PLCγ2-P522R variant in a less aggressive APP/PS1 mouse model of AD and assessed the underlying cellular mechanisms using mouse and human microglial models.

methodsThe effects of the protective PLCγ2-P522R variant on microglial activation, AD-associated β-amyloid and neuronal pathologies, and behavioral changes were investigated in PLCγ2-P522R knock-in variant mice crossbred with APP/PS1 mice. Transcriptomic, proteomic, and functional studies were carried out using microglia isolated from mice carrying the PLCγ2-P522R variant. Finally, microglia-like cell models generated from human blood and skin biopsy samples of PLCγ2-P522R variant carriers were employed.

resultsThe PLCγ2-P522R variant decreased β-amyloid plaque count and coverage in female APP/PS1 mice. Moreover, the PLCγ2-P522R variant promoted anxiety in these mice. The area of the microglia around β-amyloid plaques was also increased in mice carrying the PLCγ2-P522R variant, while β-amyloid plaque-associated neuronal dystrophy and the levels of certain cytokines, including IL-6 and IL-1β, were reduced. These alterations were revealed through [18F]FEPPA PET imaging and behavioral studies, as well as various cytokine immunoassays, transcriptomic and proteomic analyses, and immunohistochemical analyses using mouse brain tissues. In cultured mouse primary microglia, the PLCγ2-P522R variant reduced the size of lipid droplets. Furthermore, transcriptomic and proteomic analyses revealed that the PLCγ2-P522R variant regulated key targets and pathways involved in lipid metabolism, mitochondrial fatty acid oxidation, and inflammatory/interferon signaling in acutely isolated adult mouse microglia and human monocyte-derived microglia-like cells. Finally, the PLCγ2-P522R variant also increased mitochondrial respiration in human iPSC-derived microglia.

conclusionsThese findings suggest that the PLCγ2-P522R variant exerts protective effects against β-amyloid and neuronal pathologies by increasing microglial responsiveness to β-amyloid plaques in APP/PS1 mice. The changes observed in lipid/fatty acid and mitochondrial metabolism revealed by the omics and metabolic assessments of mouse and human microglial models suggest that the protective effects of the PLCγ2-P522R variant are potentially associated with increased metabolic capacity of microglia.

Indexed as

Alzheimer DiseaseMicrogliaPhospholipase C gammaAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicPlaque, AmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorPhospholipase C gammaAlzheimer’s diseaseLipid dropletsMicrogliaPhospholipase C gamma 2PLCγ2-P522R variantβ-amyloid pathology

Identifiers

PMID40038760
PMCPMC11881468

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.